The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Rediscovering Beta-2 Microglobulin As a Biomarker across the Spectrum of Kidney Diseases
Open accessAbstract
There is currently an unmet need for better biomarkers across the spectrum of renal diseases. In this paper, we revisit the role of Beta 2 microglobulin (β2M) as a biomarker in patients with Chronic Kidney Disease (CKD) and End Stage Renal Disease (ESRD). Prior to reviewing the numerous clinical studies in the area, we describe the basic biology of β2M, focusing in particular on its role in maintaining the serum albumin levels and reclaiming the albumin in tubular fluid through the actions of the neonatal Fc receptor. Disorders of abnormal β2M function arise as a result of altered binding of β2M to its protein cofactors and the clinical manifestations are exemplified by rare human genetic conditions and mice knockouts. We highlight the utility of β2M as a predictor of renal function and clinical outcomes in recent large database studies against predictions made by recently developed whole body population kinetic models. Furthermore, we discuss recent animal data suggesting that contrary to textbook dogma urinary β2M may be marker for glomerular rather than tubular pathology. We review the existing literature about β2M as a biomarker in patients receiving renal replacement therapy, with particular emphasis on large outcomes trials. We note emerging proteomic data suggest that β2M is a promising marker of Chronic Allograft Nephropathy. Finally, we present data about the role of β2M as a biomarker in a number of non-renal diseases. The goal of this comprehensive review is to direct attention to the multi-faceted role of β2M as a biomarker, and its exciting biology in order to propose the next steps thar are required to bring this recently rediscovered biomarkers into the 21st century.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Telmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346
Palumbo, A., Avet-Loiseau, H., Oliva, S., Lokhorst, H. M., Goldschmidt, H., Rosinol, L., Richardson, P., Caltagirone, S., Lahuerta, J. J., Facon, T., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.2267 · Cited by 2,210
Cardiorenal end points in a trial of aliskiren for type 2 diabetes
Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208799 · Cited by 1,319
Combined angiotensin inhibition for the treatment of diabetic nephropathy
Fried, L. F., Emanuele, N., Zhang, J. H., Brophy, M., Conner, T. A., Duckworth, W., Leehey, D. J., McCullough, P. A., O'Connor, T., Palevsky, P. M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303154 · Cited by 1,169
An Fc receptor structurally related to MHC class I antigens
Simister, N. E., & Mostov, K. E. (1989) · Nature · doi:10.1038/337184a0 · Cited by 729
Chaudhury, C., Mehnaz, S., Robinson, J. M., Hayton, W. L., Pearl, D. K., Roopenian, D. C., & Anderson, C. L. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021829 · Cited by 640
Kim, J., Hayton, W. L., Robinson, J. M., & Anderson, C. L. (2007) · Clinical Immunology · doi:10.1016/j.clim.2006.09.001 · Cited by 208
Schaible, U. E., Collins, H. L., Priem, F., & Kaufmann, S. H. E. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020897 · Cited by 198
Suzuki, T., Agarwal, S. K., Deo, R., Sotoodehnia, N., Grams, M. E., Selvin, E., Calkins, H., Rosamond, W., Tomaselli, G., Coresh, J., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.07.004 · Cited by 38
Cited by
An aged immune system drives senescence and ageing of solid organs
Yousefzadeh, M. J., Flores, R. R., Zhu, Y., Schmiechen, Z. C., Brooks, R. W., Trussoni, C. E., Cui, Y., Angelini, L., Lee, K.-A., McGowan, S. J., et al. (2021) · Nature · doi:10.1038/s41586-021-03547-7 · Cited by 972
Yao, C., Chen, G., Song, C., Keefe, J., Mendelson, M., Huan, T., Sun, B. B., Laser, A., Maranville, J. C., Wu, H., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05512-x · Cited by 431
Shi, F., Sun, L., & Kaptoge, S. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.01.018 · Cited by 70
Glazyrin, Y. E., Veprintsev, D. V., Ler, I. A., Rossovskaya, M. L., Varygina, S. A., Glizer, S. L., Zamay, T. N., Petrova, M. M., Minic, Z., Berezovski, M. V., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134802 · Cited by 35
Metadata
- Authors
- Argyropoulos, C. P., Chen, S. S., Ng, Y.-H., Roumelioti, M.-E., Shaffi, K., Singh, P. P., & Tzamaloukas, A. H.
- Venue
- Frontiers in Medicine
- Publisher
- Frontiers Media SA
- Published
- 2017-06-15
- Volume
- 4
- Pages
- 73-73
- ISSN
- 2296-858X (ISSN-L)
- OpenAlex
- W2735466792
- Cited by
- 308
- References
- 11
- FWCI
- 15.04
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
